Legislation Includes Measures to Increase Patient and Expert Participation in FDA Review of Rare Disease Drugs
Site Search
The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.
Preston W. Campbell, III, President and CEO to retire; Michael P. Boyle, MD, appointed as successor effective January 2020.
The Cystic Fibrosis Foundation has announced the recipients of its first annual Impact Grants.
Read our statement on tobacco entity involvement.
Mascaro Construction employees have a strong track record of giving back to advance the CF Foundation’s mission. A giving culture is what the late founder, Jack Mascaro, first established when he started the highly successful company.
Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab